Critically evaluate India's phased approach to introducing new vaccines under the Universal Immunization Programme, using PCV as a case study.

Pneumonia, largely caused by Streptococcus pneumoniae, accounts for about 16% of under-five deaths in India [1]. The Pneumococcal Conjugate Vaccine (PCV) was therefore introduced in stages — a limited launch in 2017 followed by nationwide rollout — making it a useful test of whether phasing strengthens or delays India's immunisation goals.

The phased model in practice

• PCV was first introduced in 2017 in parts of Himachal Pradesh, Bihar and Uttar Pradesh, states carrying a high child-mortality burden [2].
• Nationwide expansion under the UIP was launched as part of Azadi ka Amrit Mahotsav, extending free vaccination to the entire annual birth cohort (~2.7 crore children) on a 3-dose schedule (6 weeks, 14 weeks, booster at 9–12 months) [1].

Merits of phasing

• Burden-based prioritisation: high-mortality states received protection first, advancing equity rather than uniform but slower coverage.
• Systems readiness: staggering allowed cold-chain augmentation, health-worker training and AEFI surveillance to mature before scale-up.
• Fiscal and supply realism: conjugate vaccines are costly and supply-constrained; phasing matched procurement to indigenous manufacturing capacity.
• Federal fit: delivery rests with state health systems under MoHFW coordination, so calibrated entry suits varying state capacity.

Limitations

• Delayed universalisation: children outside pilot states remained unprotected for several years, an avoidable mortality cost.
• Inter-state inequity during the interim, and dependence on weaker states' outreach for the last mile.
• Scientific ceiling: PCVs protect only against selected serotypes out of roughly 100; serotype replacement by non-vaccine serotypes can erode gains, a concern WHO flags for routine programmes [3]. Research toward a serotype-independent "universal" vaccine is still at an early stage [4].
• Phasing addresses delivery, not surveillance gaps in tracking circulating serotypes.

On balance, phasing has been a prudent, capacity-sensitive strategy that ultimately delivered universal free access. Its value can be raised by compressing rollout timelines, strengthening serotype surveillance and sustaining indigenous vaccine R&D — aligning UIP with the right to health under Article 21 and SDG-3's child-survival targets.